AlloVir (NASDAQ:ALVR) Issues Quarterly Earnings Results, Beats Expectations By $0.10 EPS

AlloVir (NASDAQ:ALVR) released its earnings results on Tuesday. The company reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.10, reports.

AlloVir Stock Down 1.8 %

Shares of ALVR opened at $0.55 on Friday. AlloVir has a 1 year low of $0.53 and a 1 year high of $2.49. The business’s 50 day simple moving average is $0.79 and its 200-day simple moving average is $0.77.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in ALVR. Acadian Asset Management LLC lifted its stake in shares of AlloVir by 694.6% in the 1st quarter. Acadian Asset Management LLC now owns 1,587,451 shares of the company’s stock valued at $1,197,000 after purchasing an additional 1,387,666 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its stake in AlloVir by 127.4% during the first quarter. Price T Rowe Associates Inc. MD now owns 97,986 shares of the company’s stock worth $74,000 after buying an additional 54,900 shares during the period. Point72 Asia Singapore Pte. Ltd. bought a new position in AlloVir during the 2nd quarter valued at about $55,000. Finally, Cubist Systematic Strategies LLC raised its position in AlloVir by 152.3% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 49,816 shares of the company’s stock worth $36,000 after purchasing an additional 30,072 shares during the period. Hedge funds and other institutional investors own 66.05% of the company’s stock.

About AlloVir

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus.